




WEST VIRGINIA  
DRUG UTILIZATION REVIEW  
BOARD MEETING

---

February 25, 2026



- **Rachele Poissant, PharmD**  
Clinical Account Manager
  - **Cory Chambliss**  
Operations Director
  - **Scott Donald, PharmD**  
Director of Clinical Services
- 
- 



# RDUR Patient Reviews

	Target Intervention	Profiles Reviewed	Letters Sent	Response Rate
Oct	Off-label Use of Montelukast	597	692	7%
Nov	Cardiometabolic Adverse Effects	600	753	2%
Dec	Additional Anticholinergic Effects	608	571	4%



# RDUR Patient Reviews

---

**October 2025:**

Off-label Use of Montelukast

Drugs included:

- Montelukast

- Singulair (montelukast) is FDA-approved for the treatment of asthma, allergic rhinitis, and exercised-induced bronchoconstriction. There is insufficient data available to warrant the use of this medication in other disease states. Inappropriate use of medication can lead to decreased patient outcomes and increased medical costs.



# RDUR Patient Reviews

---

**November 2025:**

Cardiometabolic Adverse Effects

Drugs included:

- Clozapine
- Olanzapine
- Risperidone
- Quetiapine

- The patient has (specified disease state) and is receiving an antipsychotic that has a moderate to high risk for cardiometabolic disorders. Patients with major mental illness (e.g., schizophrenia and bipolar disorder) have increased risks of morbidity and mortality, due primarily to cardiovascular disease. If possible, consider an antipsychotic agent that has a more favorable cardiometabolic adverse effect profile. All patients prescribed an antipsychotic agent should receive baseline screening for personal and family history of obesity, diabetes, dyslipidemia, hypertension, and cardiovascular disease. The therapeutic benefits achieved with moderate- to high-risk antipsychotics may be offset by the reduction in life expectancy related to drug induced cardiometabolic disease.



# RDUR Patient Reviews

---

## December 2025:

### Additional Anticholinergic Effects

#### Drugs included:

- Antidepressants
- Cyclobenzaprine
- Antihistamines
- Benztropine
- Atropine
- Oxybutynin
- Scopolamine
- Anticholinergic effects

- Concurrent use of the (specified drug class) and another agent with anticholinergic properties may produce additive anticholinergic effects.



# RDUR Outcomes Report

	Criteria	PRE Targeted Patients with Hits	POST Targeted Patients with Hits	POST Targeted Patients with Change
April 2025	Antihyperlipidemic Drug Interactions	381	190	50.13%
May 2025	Increased Risk of Serotonin Syndrome	363	137	62.26%
June 2025	Increased Risk of QT Prolongation	356	158	55.62%
<b>Total</b>		<b>1,100</b>	<b>485</b>	<b>55.91%</b>



# Lock-In Interventions

Month	Reviewed	Warning Letter	Locked In
July	75	0	0
August	75	3	2
Sept	75	0	0
<b>Totals</b>	<b>225</b>	<b>3</b>	<b>2</b>



# 2025 Fourth Quarter Newsletter

## **FDA Approval Spotlight**

### Hereditary Angioedema

- Orladeyo (berotralstat) Pellets
- Dawnzera (donidalorsen)
- Andembry (garadacimab)

## **2025 Guideline Update**

- American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia



Acentra

HEALTH

Accelerating  
Better Outcomes